➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKesson
Dow
Boehringer Ingelheim
Medtronic

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 10,434,172

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,434,172
Title:Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter alia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.
Inventor(s): Papavassilis; Charis (Lorrach, DE), Sander; Oliver (Basel, CH), Shima; Tomohiro (Tokyo, JP), Kitamura; Susumu (Yokohama, JP)
Assignee: Novartis AG (Basel, CH)
Application Number:14/911,387
Patent Claims:see list of patent claims

Details for Patent 10,434,172

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Janssen Biotech STELARA ustekinumab INJECTABLE;INJECTION 761044 001 2019-11-07   Start Trial Novartis AG (Basel, CH) 2033-08-15 RX search
Novartis Pharms Corp COSENTYX secukinumab INJECTABLE;INJECTION 125504 001 2016-01-15   Start Trial Novartis AG (Basel, CH) 2033-08-15 RX search
Centocor Ortho Biotech Inc STELARA ustekinumab INJECTABLE; INJECTION 125261 002 2009-12-30   Start Trial Novartis AG (Basel, CH) 2033-08-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Baxter
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.